Seelos Therapeutics Inc [NASDAQ: SEEL] plunged by -$0.03 during the normal trading session on Monday and reaching a high of $0.1484 during the day while it closed the day at $0.12. The company report on October 27, 2023 at 8:11 AM that Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer’s Disease at Neuroscience 2023.
-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis and Spinocerebellar ataxia.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster from a study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in a tauopathy model of Alzheimer’s disease at the Society for Neuroscience’s Neuroscience 2023 meeting, to be held on November 11-15, 2023, at the Walter E. Washington Convention Center in Washington, D.C.
Seelos Therapeutics Inc stock has also loss -30.67% of its value over the past 7 days. However, SEEL stock has declined by -89.45% in the 3 months of the year. Over the past six months meanwhile, it has lost -86.42% and lost -81.83% year-on date.
The market cap for SEEL stock reached $18.45 million, with 149.50 million shares outstanding and 146.26 million shares in the current float. Compared to the average trading volume of 5.12M shares, SEEL reached a trading volume of 5643896 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Seelos Therapeutics Inc [SEEL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SEEL shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SEEL stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Seelos Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 27, 2021.
The Average True Range (ATR) for Seelos Therapeutics Inc is set at 0.03, with the Price to Sales ratio for SEEL stock in the period of the last 12 months amounting to 16.18.
SEEL stock trade performance evaluation
Seelos Therapeutics Inc [SEEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -30.67. With this latest performance, SEEL shares dropped by -32.64% in over the last four-week period, additionally sinking by -86.42% over the last 6 months – not to mention a drop of -85.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SEEL stock in for the last two-week period is set at 24.65, with the RSI for the last a single of trading hit 20.72, and the three-weeks RSI is set at 26.88 for Seelos Therapeutics Inc [SEEL]. The present Moving Average for the last 50 days of trading for this stock 0.3572, while it was recorded at 0.1537 for the last single week of trading, and 0.8186 for the last 200 days.
Seelos Therapeutics Inc [SEEL]: An insightful look at the core fundamentals
Return on Total Capital for SEEL is now -165.32, given the latest momentum, and Return on Invested Capital for the company is -202.01. Return on Equity for this stock declined to -314.84, with Return on Assets sitting at -138.42. Additionally, SEEL Total Debt to Total Capital is recorded at 211.57, with Total Debt to Total Assets ending up at 88.46.
Reflecting on the efficiency of the workforce at the company, Seelos Therapeutics Inc [SEEL] managed to generate an average of -$4,595,875 per employee.Seelos Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.21 and a Current Ratio set at 0.21.
Seelos Therapeutics Inc [SEEL]: Institutional Ownership
The top three institutional holders of SEEL stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in SEEL stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in SEEL stock with ownership which is approximately 5.7994%.